147 related articles for article (PubMed ID: 20431561)
1. New drug approval success rate in Europe in 2009.
Eichler HG; Aronsson B; Abadie E; Salmonson T
Nat Rev Drug Discov; 2010 May; 9(5):355-6. PubMed ID: 20431561
[No Abstract] [Full Text] [Related]
2. European Medicines Agency pledges to publish clinical reports.
Watson R
BMJ; 2014 Oct; 349():g6086. PubMed ID: 25294699
[No Abstract] [Full Text] [Related]
3. European Medicines Agency-Health Technology Assessment Parallel Consultation Platform: An Industry Perspective.
Khan S; Carter M
Clin Pharmacol Ther; 2019 Apr; 105(4):822-825. PubMed ID: 30811582
[No Abstract] [Full Text] [Related]
4. EU court gets tough on patent extensions for combo products.
Waters H
Nat Med; 2012 Jan; 18(1):4. PubMed ID: 22227647
[No Abstract] [Full Text] [Related]
5. Regulatory science as a bridge between science and society.
Tominaga T; Asahina Y; Uyama Y; Kondo T
Clin Pharmacol Ther; 2011 Jul; 90(1):29-31. PubMed ID: 21691273
[TBL] [Abstract][Full Text] [Related]
6. Biopharmaceutical benchmarks 2006.
Walsh G
Nat Biotechnol; 2006 Jul; 24(7):769-76. PubMed ID: 16841057
[TBL] [Abstract][Full Text] [Related]
7. New drug approvals for 2002.
Frantz S; Smith A
Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
[No Abstract] [Full Text] [Related]
8. Researchers see a need for speed in EU trial approvals.
Cressey D
Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
[No Abstract] [Full Text] [Related]
9. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
10. Statisticians in European regulatory agencies.
Skovlund E
Pharm Stat; 2009; 8(4):259-63. PubMed ID: 19301357
[TBL] [Abstract][Full Text] [Related]
11. Expanded EU presents promise and challenges.
Vermij P
Nat Rev Drug Discov; 2004 May; 3(5):377-8. PubMed ID: 15152627
[No Abstract] [Full Text] [Related]
12. Raising the game.
Nat Biotechnol; 2008 Feb; 26(2):137. PubMed ID: 18259155
[No Abstract] [Full Text] [Related]
13. Industry concern over EU hepatotoxicity guidance.
Hughes B
Nat Rev Drug Discov; 2008 Sep; 7(9):719. PubMed ID: 19172685
[No Abstract] [Full Text] [Related]
14. Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid: Balancing the Risks for Male Allograft Recipients.
Kuypers DR; Van Mieghem T; Meijers B; Claes K
Transplantation; 2016 Sep; 100(9):e50-1. PubMed ID: 27472093
[No Abstract] [Full Text] [Related]
15. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
Milton MN; Horvath CJ
Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
[No Abstract] [Full Text] [Related]
16. "Bonne Année", "Gutes Neues Jahr"? Will 2007 be a "Happy New Year" for children's medicines in Europe?
Stephenson T
Arch Dis Child; 2007 Aug; 92(8):661-3. PubMed ID: 17642477
[TBL] [Abstract][Full Text] [Related]
17. EMEA approves OGS drug rejected by FDA.
Mitchell P
Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
[No Abstract] [Full Text] [Related]
18. Pharmaceutical regulation in the European Community: barriers to single market integration.
Orzack LH; Kaitin KI; Lasagna L
J Health Polit Policy Law; 1992; 17(4):847-68. PubMed ID: 1299692
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceuticals, the state and the global harmonisation process.
Abraham J
Aust Health Rev; 2004 Nov; 28(2):150-60. PubMed ID: 15527395
[TBL] [Abstract][Full Text] [Related]
20. Lessons from Eprex for biogeneric firms.
Louët S
Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
